Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset

Plus, news about ArriVent BioPharma, Everest Medicines, Ribocure, Paradigm Biopharmaceuticals, Verrica and Torii: Organon discontinues experimental therapy for endometriosis-related pain: The Merck spinout said the drug did not meet the primary ...